{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:03:42Z","timestamp":1788969822749,"version":"build-2803163510"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015739","name":"Bayer Vital GmbH","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Behandlung \u00e4lterer Patienten erfordert eine besondere Aufmerksamkeit f\u00fcr Arzneimittelinteraktionen, da mit einer Zunahme der altersbedingten Morbidit\u00e4t eine Polypharmazie immer relevanter wird. Insbesondere bei Medikamenten mit einer geringen therapeutischen Breite k\u00f6nnen Arzneimittelinteraktionen klinische Konsequenzen haben, die eine Anpassung der Dosis oder das Beenden oder Wechseln der Begleitmedikation erfordern. Oft sind diese Interaktionen auf eine pharmakokinetische Ver\u00e4nderung des Arzneimittelabbaus \u00fcber das Cytochrom-P450(CYP)-Enzymsystem zur\u00fcckzuf\u00fchren, vor allem \u00fcber CYP3A4. Diese Enzymisoform ist an dem Metabolismus von etwa der H\u00e4lfte der therapeutisch verwendeten Arzneimittel beteiligt, sodass sich auch viele CYP3A4-Substrate unter den eingesetzten Medikamenten bei Prostatakrebspatienten befinden. Unter den starken CYP3A4-Induktoren Apalutamid und Enzalutamid sind in diesem Zusammenhang \u2013 im Gegensatz zu Darolutamid \u2013 in vielen F\u00e4llen deutlich erniedrigte Plasmakonzentrationen bei den gleichzeitig verabreichten Arzneimitteln zu erwarten. Bei Abirateron handelt es sich hingegen um einen moderaten CYP2D6-Inhibitor. Da \u00fcber dieses Isoenzym deutlich weniger Wirkstoffe biotransformiert werden, ist das Interaktionsspektrum anders zu bewerten. Um im Vorfeld einer Pharmakotherapie das Ausma\u00df einer Wechselwirkung besser absch\u00e4tzen zu k\u00f6nnen, ist es hilfreich, die Abbauwege der einzelnen Wirkstoffe besser zu verstehen, um im Zweifel rechtzeitig das Therapiemonitoring intensivieren, Dosisver\u00e4nderungen und Wechsel einer Pharmakotherapie vornehmen zu k\u00f6nnen.<\/jats:p>","DOI":"10.1055\/a-2593-1605","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:20:09Z","timestamp":1749075609000},"page":"284-300","source":"Crossref","is-referenced-by-count":2,"title":["Androgenrezeptor-gerichtete Therapien \u2013 klinisch relevante Interaktionen vermeiden"],"prefix":"10.1055","volume":"57","author":[{"given":"Hans-Peter","family":"Lipp","sequence":"additional","affiliation":[{"name":"Universit\u00e4t T\u00fcbingen, Germany","place":["T\u00fcbingen"],"department":["Lehrbeauftragter f\u00fcr Pharma\u00f6konomie und -epidemiologie, Pharmazeutisches Institut"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany","place":["Hamburg"],"department":["Onkologisches Zentrum\/ Martini-Klinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein, Campus L\u00fcbeck, Germany","place":["L\u00fcbeck"],"department":["Urology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Rausch","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik T\u00fcbingen, Germany","place":["T\u00fcbingen"],"department":["Klinik f\u00fcr Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Sch\u00f6ning","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Heidelberg, Baden-W\u00fcrttemberg, Germany","place":["Heidelberg"],"department":["Universit\u00e4tsapotheke"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[{"name":"Urologie Bayenthal in K\u00f6ln, Germany","place":["K\u00f6ln"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Erlangen, Germany","place":["Erlangen"],"department":["Urologische und kinderurologische Klinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"CJ Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"K Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"JS de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00228-018-2501-x","article-title":"Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans","volume":"74","author":"KA Kim","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"H Bolek","year":"2024","journal-title":"ESMO Open"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3332\/ecancer.2016.611","article-title":"Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015","volume":"10","author":"R Stepney","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial","volume":"14","author":"N Shore","year":"2019","journal-title":"Target Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9343(86)90847-8","article-title":"Pharmacokinetics of terazosin","volume":"80","author":"RC Sonders","year":"1986","journal-title":"Am J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies","volume":"44","author":"C Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref23","first-page":"LBA68","article-title":"Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARANOTE trial","volume":"35","author":"F Saad","year":"2024","journal-title":"ESMO"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"K Fizazi","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"M Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"MR Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010","volume":"13","author":"B Guthrie","year":"2015","journal-title":"BMC Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"h949","DOI":"10.1136\/bmj.h949","article-title":"Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines","volume":"350","author":"S Dumbreck","year":"2015","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","article-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","volume":"14","author":"E Basch","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1006\/bbrc.1993.1457","article-title":"Biotransformation of Pravastatin Sodium(I): Mechanisms of Enzymatic Transformation and Epimerization of an Allylic Hydroxy Group of Pravastatin Sodium","volume":"192","author":"E Kitazawa","year":"1993","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tips.2012.03.001","article-title":"Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications","volume":"33","author":"A Tornio","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jcin.2012.10.005","article-title":"Drug-drug interactions in cardiovascular catheterizations and interventions","volume":"5","author":"SP Dunn","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1078-0432.CCR-17-2336","article-title":"Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients","volume":"24","author":"BPS Belderbos","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","article-title":"Drug-drug interactions of non-vitamin K oral anticoagulants","volume":"12","author":"C Voukalis","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cger.2016.06.006","article-title":"The Role of Opioid Analgesics in Geriatric Pain Management","volume":"32","author":"JG Naples","year":"2016","journal-title":"Clin Geriatr Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/cts.13229","article-title":"Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters","volume":"15","author":"S Poondru","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/01.fpc.0000236339.79916.07","article-title":"UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin","volume":"17","author":"Y Chen","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jcpt.13058","article-title":"Clinically relevant drug interactions between statins and antidepressants","volume":"45","author":"C Palleria","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/FTD.0b013e3182708f84","article-title":"UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients","volume":"34","author":"T Fukuda","year":"2012","journal-title":"Ther Drug Monit"},{"key":"ref60","first-page":"83","article-title":"Klinisch relevante Interaktionen zwischen Analgetika und Psychopharmaka","volume":"30","author":"D Strobach","year":"2012","journal-title":"Arzneimitteltherapie"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"RS Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"key":"ref63","first-page":"15","article-title":"Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential","volume":"62","author":"MB Chancellor","year":"2007","journal-title":"Geriatrics"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"ZH Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.clpt.2004.08.024","article-title":"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide","volume":"76","author":"SV Vormfelde","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11523-022-00932-8","article-title":"Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases","volume":"18","author":"G Brown","year":"2023","journal-title":"Target Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"S1240","DOI":"10.1016\/S0302-2838(21)01259-8","article-title":"Gross hematuria and anticoagulation \u2013 Critical evaluation of clinical outcome predictors and underlying urological pathology in hospitalized patients","volume":"79","author":"L Lawaczeck","year":"2021","journal-title":"European Urology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.3390\/cancers12113369","article-title":"The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes","volume":"12","author":"DG Hu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/tpj.2011.44","article-title":"Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver","volume":"13","author":"A Schroder","year":"2013","journal-title":"Pharmacogenomics J"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2593-1605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:33:28Z","timestamp":1780439608000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2593-1605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":35,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,6,2]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2593-1605","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}